Search Results - liping+xu




1 Results Sort By:
A method to induce ferroptosis and to downregulate androgen receptor/androgen receptor splice variant in prostate cancer cells
Prostate cancer (PCa) effects approximately three million men in the United States every year. About 10-20% of the cases of prostate cancer are castrate-resistant prostate cancer (CRPC). This form of PCa is highly resistant to what Is known as androgen depletion therapy and is often fatal. All types of PCa are sensitive to androgen receptor signaling...
Published: 11/19/2020   |   Inventor(s): Zhihui Qin, Liping Xu
Keywords(s): Anti-cancer, Cancer, Cancer Therapies, Drug Delivery, Drug Target, Prostate Cancer
Category(s): Medical, Diseases, Drug Discovery, Pharmaceuticals, Oncology